Dirk Pleimes

Dirk Pleimes, M.D., is Chief Executive Officer of Pentixapharm Holding AG, a clinical-stage radiopharmaceutical company advancing targeted diagnostics and therapies based on its CXCR4 platform. With deep experience across biotech leadership, clinical development, financing and corporate strategy, Dirk is driving Pentixapharm’s transition from a European start-up platform into a lean, execution-focused radiopharmaceutical company. Its Phase 3 lead program, [⁶⁸Ga]Ga-PentixaFor, is being developed as a first-in-class, first-in-indication approach to transform patient stratification in hypertension due to primary aldosteronism, while its theranostic pipeline includes [⁹⁰Y]Y-PentixaTher and glycoform-specific CD24 antibody programs. Dirk focuses on evidence, partnerships and value for patients, physicians and shareholders.